Affymetrix reiterated its commitment to deliver on three main business priorities to reinvigorate its gene-expression and genotyping businesses after a year of sluggish sales attributed to declining demand for its array products amid weak pharma spending.

According to CEO Kevin King, Affy's three-pronged strategy includes targeting downstream genomicanalysis markets with the new products gained through its acquisitions of Panomics and True Materials last year; rolling out new genotyping assays on its GeneTitan array platform, and consolidating its manufacturing facilities.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Technology Review reports that researchers in the US have used CRISPR to modify a number of human embryos.

By introducing genes from butterfly peas and Canterbury bells, researchers in Japan have developed a blue chrysanthemum, according to NPR.

Plant researchers plan to sequence some 10,000 samples that represent the major plant clades, ScienceInsider reports.

In Nature this week: a Danish reference genome, and more.